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Abstract
Pituitary tumors are common in the general population. Since neuroimaging techniques have improved,
pituitary tumors are more often diagnosed incidentally. About 16.7% of the general population show
changes in the pituitary gland. Predominantly, pituitary tumors are benign pituitary adenomas. Pituitary
carcinomas or aggressive pituitary tumors are extremely rare. They might develop from benign adenomas.
New genetic and epigenetic abnormalities help us to understand pituitary tumorigenesis and might lead to
therapeutical targeting drugs in the future. Macroadenomas (>1 cm) can lead to visual field disturbances,
compression of cranial nerves, hypopituitarism, and infiltration of the cavernous sinuses. The functional
status of the pituitary tumor is important. About half to one third of all pituitary tumors are non-functioning
pituitary adenomas. The other pituitary tumors show a specific pattern of hormone secretion. About
25% to 41% of all pituitary tumors are prolactinomas, acromegaly with production of growth hormone
represents 10% to 15% of adenomas, Cushing’s disease with production of adrenocorticotropic hormone
accounts for 10%, and other hormonal characteristics are less common. Transsphenoidal resection and
total adenomectomy are desirable. Radiosurgery has enriched the surgical treatment options. Surgical
treatment is the intervention of choice except for prolactinomas, where pharmaceutical treatment
is recommended. Pharmaceutical treatment consists of dopamine agonists such as cabergoline and
somatostatin analogues that include octreotide and pasireotide; retinoic acid is of theoretical interest
while peroxisome proliferator-activated receptor-gamma-ligands are not clinically useful. In acromegaly,
pegvisomant is a further treatment option. Temozolomide should be considered in aggressive pituitary
tumors. In general, pharmaceutical options developed recently have extended the repertoire of treatment
possibilities of pituitary tumors.
Recent advances
Epidemiology
Pituitary tumors are common in the general population.
In 16.7%, changes in the pituitary gland can be detected
[1]. Since neuroimaging techniques have recently
improved, pituitary tumors aremore frequently diagnosed
incidentally.
Usually, pituitary tumors are assigned as primary tumors
of the central nervous system (CNS) and contribute to 5%
to 20% of all primary CNS tumors [2]. In 95% of cases,
pituitary tumors occur sporadically. Only in 5% may a
familial genetic background be assumed, e.g. as part of
Multiple Endocrine Neoplasia (MEN) Type 1, Carney’s
Complex (CNC), or Familial Isolated Pituitary Adenomas
(FIPAs). In MEN1 syndrome, pituitary tumors occur along-
side (entero-) pancreatic tumors, parathyroid hyperplasia,
lipomas, and angiofibromas. This autosomal-dominant
syndrome contributes to 2.7% of all pituitary tumors [3].
In most cases, pituitary tumors are benign adenomas.
Pituitary carcinomas are extremely rare, and in these cases
the assumption is that they are former benign adenomas
that have undergone additional genetic mutations [4].
These changes induce an invasive tumor progression and
the development of metastasis, mainly into the brain or
spinal cord. Distant metastasis can be found in the liver,
lung, or lymph nodes.
Page 1 of 6
(page number not for citation purposes)
Published: 02 January 2014
© 2014 Faculty of 1000 Ltd
In childhood, craniopharyngiomas occur with an inci-
dence of 0.5-2/million/year. Survival rates after surgical
treatment are rather high: between 91% and 98% [5].
Pituitary adenomas are classified partially depending on
their size into microadenomas (<1 cm) and macroade-
nomas (>1 cm). The size of the adenoma corresponds
with compromising effects on the optic chiasm, cranial
nerves, and cavernous sinuses, but tumor size does not
reflect its clinical importance [6]. This classification is
supplemented by immunochemistry and functional
status. Pituitary tumors are classified as functioning or
non-functioning on the basis of their ability to produce
and secrete mature hormones [1,7]. Approximately half
to one third of all pituitary tumors are non-functioning
pituitary adenomas (NFPAs) (i.e. without hormone
secretion detected either by immohistochemistry or by
elevated hormonal blood levels). The most common
hormone-secreting pituitary tumor is the prolactinoma
(lactotroph adenoma – 25%-41%), followed by somato-
troph adenomas (10%-15%), corticotroph adenomas
(about 10%), thyrotroph adenomas (<1%), and gona-
dotroph adenomas (<1%) [1,8].
Pathophysiology and molecular genetics
Pituitary tumors are mostly monoclonal. Therefore,
genetic influences in only one cell might induce tumor
transformation. In sporadic tumors, gsp oncogene is the
most important one. Mutations in the alpha subunit of
G protein gene — which is involved in hypothalamic
growth hormone (GH) release—might cause continuous
activation of adenylyl cyclase [2]. This pattern was
observed in 40% of GH-secreting tumors (somatotropi-
nomas). Usually the alpha subunit of the G protein gene is
expressed monoallelically, whereas in some cases it is
expressed biallelically and this is through a process termed
loss of imprinting [9].
About 15%of all FIPA patients showmutations in the aryl
hydrocarbon receptor-interacting protein (AIP) gene. This
chaperone might act as a tumor suppressor; mutations
might induce tumorigenesis [10]. Clinically, patients with
FIPA are younger and show bigger pituitary adenomas at
diagnosis.
The number of genes and molecular abnormalities
involved in pituitary tumorigenesis increased in the last
years [11]. In some cases genetic changes were associated
with specific types of pituitary adenomas such as the
promotion of somatotroph pituitary tumorigenesis
through the FGFR4-G388R polymorphism [12]. In spite
of genetic changes, pituitary tumors show epigenetic
changes as different histone modification and aberrant
DNAmethylation status [13]. These genetic and epigenetic
changes might be of interest for the development of new
drugs. Further investigations and studies are therefore
necessary.
Diagnosis
Since magnetic resonance imaging (MRI) techniques
have improved and are used more widely in the general
population, pituitary adenomas are more frequently
diagnosed incidentally. Pituitary tumors such as NFPA
might not be identified for many years. In contrast, macro-
adenomas can cause local symptoms such as visual dis-
turbances when the optic chiasm is compressed.
Even small pituitary adenomas might have clinically
important consequences through elevated hormonal
levels and become apparent as hyperprolactinaemia,
GH, or cortisol excess. In these patients, endocrinological
disturbances can lead to secondary hypogonadism due to
hyperprolactinaemia, acromegaly, or Cushing’s disease
(CD). Interestingly, the tumor size in prolactinomas
correlates with serum prolactin levels [14]. Inmost patients
with prolactin levels >250 µg/l, a (macro)prolactinoma
might be assumed. In acromegaly, patients show a typical
facial appearance and acral enlargement. The diagnosis can
be confirmed by elevated basal GH levels (>0.4 µg/l),
elevated basal insulin-like growth factor-1 (IGF-1) levels
(depending on age-related normal values), and a lack of
suppression of GH in the oral glucose tolerance test with
75 g glucose load (GH >1 µg/l) [15]. In CD, typical clinical
symptoms such as abdominal fat distribution, red striae,
and muscle weakness can lead to the suspicion of Cushing
syndrome [16]. To verify suspected CD, 24-hour urinary
cortisol level or a dexamethasone suppression test (1-2mg)
is recommended [17].
Even when neuroimaging techniques have improved,
microadenomas can be difficult to detect in MRI and even
later during surgery. Before surgery, coronal and sagittal
T1-weighted sections through the sella are required. MRI
scans should be performed before and after contrast
enhancement [18]. In order to detect small hormonal
active pituitary adenomas, selective catheterization of the
inferior petrosal sinuses can be conducted [17].
The visual field and cranial nerve function have to be
evaluated, especially in macroadenomas. MRI techniques
help to identify invasion of the cavernous sinuses or
suprasellar tumor growth and this is important for the
surgical approach [19].
Surgical treatment
Surgical treatment is the first-line treatment in pituitary
adenomas— except for prolactinomas, where dopamine
agonists are recommended as treatment of choice [20,21].
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Two operative techniques exist for resection of pituitary
tumors. Transsphenoidal (transnasal) resection is the most
common operative technique; only in extrasellar tumors
is a craniotomy recommended. Intraoperative MRI scans
might ameliorate outcome in some patients but are not
generally recommended [22,23]. Recently, stereotactic and
fractional radiosurgery such as Gamma Knife or Cyber
Knife have enriched interventional treatment options [24].
Selective adenomectomy is the treatment of choice in order
to preserve pituitary function [18]. In CD, surgical curative
therapy is the treatment of choice in adrenocorticotropic
hormone (ACTH)-producing tumors [21]. On the first day
post-surgery, cortisol levels should be determined. Fasting
serum cortisol levels <50 nmol/l (<2 µg/dl) indicate a
remission and a low recurrence rate (10% after 10 years).
If fasting serum cortisol levels are higher than 140 nmol/l
(5 µg/dl) in the first week post-surgery, further evaluation is
necessary [21]. In case of postsurgical hypocortisolism, a
substitution therapy should be initiated [18]. In recurrent
adenomas, irradiation or adrenalectomy should be con-
sidered as further treatment options [17].
In pituitary carcinomas, it might be necessary to repeat
surgical interventions. In most cases, surgical treatment will
be supplemented with pharmacological treatment (dopa-
mine agonists, somatostatin analogues, temozolomide).
Furthermore, radiotherapy should be evaluated in patients
with aggressive pituitary tumors when surgical and pharma-
cological treatment options fail.
Pharmacological treatment
Hormonal active pituitary adenomas can be treated
pharmacologically. In prolactinomas, pharmacological
treatment is the treatment of choice.
The dopamine D2 receptor subtype is the pharmacolo-
gical target of dopamine agonists. Dopamine inhibits
prolactin production from the pituitary gland [25]. Since
about 80% of all corticotropinomas also express the
dopamine D2 receptor [26], a normalization of cortisol
levels might be achieved using dopamine agonists such
as bromocriptine or cabergoline. Dopamime agonists
are also used in Parkinson’s disease where higher dosages
are necessary. Since ergotamine derivatives might cause
multiple fibrosis (i.e., valvular or pulmonary fibrosis)
[27,28], bromocriptine or cabergoline is only administered
with clinical controls (i.e. echocardiography). Low-dose
cabergoline with its long half-life period of 65 hours is the
most frequently used dopamine agonist for pharmacolo-
gical treatment of prolactinomas and corticotropinomas.
Clinical guidelines recommend cabergoline treatment in
patients with hyperprolactinaemia [14]. Low-dose caber-
goline does not seem to cause cardiac fibrosis [29] even as a
long-term treatment strategy. Nevertheless, echocardiogra-
phy is indicated in long-term treatmentwith higher dosages
of cabergoline >2 mg per week [30]. Cabergoline can also
be used in women who have indicated a wish to get
pregnant; it should not bewithdrawn in these patients [30].
Besides dopamine agonists, further treatment options are
available for corticotropinomas. In general, in CD either
the production of ACTH can be lowered or the cortisol
production in the adrenal gland can be reduced. New
pharmacological targets have been developed recently for
the treatment of CD.
Somatostatin analogues such as octreotide reduce ACTH
secretion. Dexamethasone and probably high levels of
corticosteroids in general reduce mRNA expression of the
somatostatin receptor type 2 (SSTR2) [31]. Since octreotide
acts via suppressionof the SSTR2, octreotide treatment is not
always successful in CD. Furthermore,most ACTH-secreting
adenomas express predominantly somatostatin receptor
type 5 (SSTR5) [32]. Recent experience exists with pasireo-
tide (SOM 230), which has a high affinity for the SSTR5
receptor but also shows affinity for the SSTR1 and SSTR2
receptors. Pasireotide may be a new effective tool in the
pharmacological treatment of corticotropinomas [33-35].
A combination of pasireotide with adrenal blocking drugs
and glucorticoid receptor antagonizing drugs might be
necessary in the individual patient [36,37].
Furthermore, it has been shown that retinoic acid can
reduce ACTH secretion and cell proliferation. The effect
is mediated by the nuclear retinoic acid receptor (RAR)
and retinoid x receptor (RXR) [38,39] and is limited to
tumors with ACTH secretion. Retinoic acid was not only
markedly suppressing ACTH secretion in corticotroph
adenoma cells in vitro but was also effective in vivo as it
strongly reduced urinary-free cortisol in patients with CD,
as shown in a recent study [40]. It has to be discussed that
only 7 patients were included in this study. Hence, human
trials are very limited, and retinoic acid is not at present an
accepted therapy.
Peroxisome proliferator-associated receptor-gamma
(PPAR-g) ligands, such as rosiglitazone, were potent
suppressors of ACTH in corticotroph cell lines in vitro or
in mouse models of CD [41] but were not clinically useful
in patients with corticotroph adenomas [42].
In acromegaly, dopamine agonists can be administered as
well as somatostatin receptor ligands or the GH receptor
antagonist pegvisomant [43]. The aim of the pharmaco-
logical treatment in acromegaly is to normalize IGF-1
levels and to decrease GH by less than 2.5 µg/l or possibly
lower.
Page 3 of 6
(page number not for citation purposes)
F1000Prime Reports 2014, 6:5 http://f1000.com/prime/reports/m/6/5
In prolactin-producing carcinomas (malignant prolacti-
nomas), temozolomide can be administered as pharma-
cological treatment [14,44,45]. In case reports,
temozolomide reduced tumor size and prolactin levels
in tumors that mainly did not express methylguanine-
DNA methyltransferase (MGMT) [46]. Since data on
MGMTmethylation status and response to temozolomide
are inconsistent in the literature, temozolomide should be
considered for all pituitary carcinomas [47].
In prolactinomas, dopamine agonists can be discontinued
after 2 years of treatment by way of trial [20]. Therefore,
serum prolactin levels have to be no longer elevated and
no tumor has to be detectable in the MRI scan [17].
Nevertheless, normal prolactin levels will persist in only
about 21% of all microprolactinomas and in about 16%
of all macroprolactinomas [48].
In nonfunctioning pituitary adenomas, no pharmacolo-
gical treatment option exists. Surgical treatment is the
treatment of choice for NFPA. Recurrence cannot be
detected by hormonal abnormalities. In incidental NFPA,
10% of microadenomas and 24% of macroadenomas
expand without treatment [49]. Surgical treatment is
indicated in case of further growth, development of visual
deficits, or hypopituitarism [49]. MRI scans should be
performed every year for the first 5 to 6 years after surgery.
In some cases (e.g. relevant tumor mass post-surgery or
invasion of the cavernous sinuses), radiotherapy is
recommended [50].
Perspectives
Recently, the new somatostatin analog pasireotide has
been established for the treatment of corticotroph pituitary
adenomas, and the application of temozolomidewas effec-
tive in a considerable proportion of patients with pituitary
carcinomas. There is evidence that inhibitors of cell sig-
naling cascades in combination with already-used drugs
(somatostatin analogs, dopamine receptor antagonists)
will further improve the pharmacological treatment of
pituitary adenomas. Moreover, recent studies have identi-
fied several genetic and epigenetic changes that are asso-
ciated with the tumorigenesis of pituitary adenomas. The
pharmacological correction of these changes will probably
open new avenues to the medical treatment of pituitary
tumors in the near future.
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